Nutrition and Pharmacological Algorithm for Oncology Patients with Anorexia

Loss of appetite, known clinically as cancerrelated anorexia, is one of the most common and distressing symptoms in patients receiving treatment for solid tumours and haematologic malignancies. It directly reduces caloric intake, accelerates weight loss, and contributes to fatigue, poorer response to therapy, and reduced quality of life. An integrated approach that combines tailored nutritional strategies with evidencebased pharmacologic agents offers the best chance of stabilising or improving nutritional status.

1. Understanding CancerRelated Anorexia

Unlike simple hunger, anorexia in oncology patients is driven by a complex interplay of factors:

• Metabolic alterations cytokines (IL1, TNF) and tumorderived factors shift metabolism toward catabolism.
• Psychological components depression, anxiety, and fear of treatment sideeffects diminish desire to eat.
• Gastrointestinal symptoms nausea, mucositis, dysgeusia, and early satiety interfere with food intake.
• Medication effects opioids, antiemetics, and certain chemotherapeutics suppress appetite.

Recognising these contributors helps clinicians choose the most appropriate interventions.

2. Initial Assessment

A systematic assessment should be performed within the first two weeks of treatment and repeated at each oncology visit.

3. Nutritional Intervention Principles

3.1 Energy & Protein Targets

For most adult oncology patients:

• Energy: 2530 kcal/kg/day (up to 35 kcal/kg/day for those with high metabolic stress).
• Protein: 1.21.5 g/kg/day (2.0 g/kg/day in catabolic states or severe sarcopenia).

Adjust targets based on tolerance, weight trends, and metabolic assessments.

3.2 Food Choice & Timing

• Small, frequent meals (56 per day) to overcome early satiety.
• Highdensity caloric foods nut butters, avocado, cheese, smoothies.
• Proteinrich snacks Greek yogurt, boiled eggs, lean deli meats.
• Flavor enhancement use herbs, citrus, or sauces to counteract dysgeusia.
• Oral nutritional supplements (ONS) when oral intake < 75% of needs.

3.3 Micronutrient Support

Deficiencies are common; a basic multivitamin with selenium and zinc is recommended unless contraindicated. Omega3 fatty acids (e.g., EPA 2g/day) may modestly improve weight and inflammation.

3.4 Enteral & Parenteral Nutrition

Consider when oral intake < 60% of needs for >1week despite optimal ONS and symptom control:

• Enteral feeding via nasogastric or PEG tube; preferred if GI tract functional.
• Parenteral nutrition reserved for severe malabsorption or obstruction; monitor glucose, electrolytes, and line infections.

4. Pharmacological Algorithm

The choice of appetitestimulating agents should be guided by the patients performance status, comorbidities, and concurrent medications.

5. Integrating Nutrition & Medication

Successful management depends on synchronising dietary advice with drug administration:

• Give corticosteroids with meals to enhance nutrient absorption and reduce gastric irritation.
• Schedule ONS or highprotein snacks 30minutes before appetitestimulating medication for maximal benefit.
• Use antiemetics (e.g., ondansetron) before meals when nausea is a barrier.
• Encourage physical activity (light walking or resistance bands) 23 times/week; it can synergise with appetite agents and preserve lean mass.

6. Monitoring & Outcomes

Continuous monitoring enables timely adjustments:

Parameter	Frequency	Goal/Target
Body weight	Weekly	Stabilisation or gain 0.5kg
Caloric intake	Daily log	75% of calculated needs
Protein intake	Weekly	1.2g/kg/day
Appetitestimulating drug sideeffects	Every visit	Minimal or manageable
Qualityoflife score (e.g., EORTC QLQC30)	Every 46weeks	Improvement or stability

7. Patient & Caregiver Education

Education empowers adherence:

• Explain the purpose and expected timeline of each medication.
• Provide printable mealplanning sheets with caloriedense recipes.
• Demonstrate how to keep a simple intake diary.
• Discuss potential sideeffects and when to call the care team.

8. Common Pitfalls & How to Avoid Them

1. Delayed assessment: Initiate screening early; waiting until severe weight loss has occurred limits the efficacy of interventions.
2. Overreliance on a single drug: Combine pharmacologic agents with nutritional counselling; rotating or adding agents prevents tachyphylaxis.
3. Ignoring drugnutrient interactions: Corticosteroids can raise blood glucose; monitor diabetic patients closely.
4. Neglecting psychosocial factors: Offer referrals to counseling, support groups, or palliativecare teams.
5. Inadequate symptom control: Treat nausea, pain, and oral mucositis aggressively before focusing on appetite.

9. Summary Checklist for Clinicians

• Screen for anorexia at each visit using a validated tool.
• Calculate individualized energy & protein targets.
• Prescribe ONS if oral intake < 75% of needs.
• Start corticosteroids for rapid appetite boost (2weeks).
• Escalate to progestins, then cannabinoids if needed.
• Address concurrent symptoms (nausea, pain, depression).
• Reassess weight, intake, and sideeffects every 24weeks.
• Educate patient/caregiver; involve dietitian and psychosocial support.

By integrating these nutritional and pharmacological strategies, oncology teams can mitigate the detrimental effects of anorexia, preserve lean body mass, and enhance overall treatment tolerance and quality of life.